Adenovirus-mediated Expression of P33(ING1b) Induces Apoptosis and Inhibits Proliferation in Gastric Adenocarcinoma Cells in Vitro

Overview

Journal Gastric Cancer

Specialties Gastroenterology
Oncology

Date 2012 Jan 13

PMID 22237655

Citations 4

Authors

Yifei Lv

Bibek Kumar Purbey

Yanhua Huang

Shuang Li

Gurung Radha

Zhiming Hao

Affiliations

Soon will be listed here.

Abstract

Background: Inhibitor of growth 1b (ING1b) is considered to be a class II tumor suppressor gene. Although reduced expression of p33(ING1b) has been reported in many human malignancies, including gastric cancers, the effect of p33(ING1b) on gastric cancer cells has yet to be investigated.

Methods: Expression of p33(ING1b) in gastric adenocarcinoma tissues and their adjacent non-malignant gastric mucosa, as well as in gastric adenocarcinoma cell lines and normal gastric epithelial cells, was detected by using Western blotting. Recombinant adenoviruses were prepared to mediate the ectopic expression of p33(ING1b) (Ad-ING1b) and green fluorescent protein (GFP)(Ad-GFP) in the gastric adenocarcinoma cell lines, SGC-7901, MKN28, and MKN45 and the normal gastric epithelial cell line GES-1. Alterations in the proliferation and apoptosis of the cells after adenoviral infection were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry, respectively, and cell cycle distribution was analyzed in a fluorescence-activated cell sorter.

Results: Western blotting confirmed the reduced expression of p33(ING1b) in gastric adenocarcinoma tissues and gastric adenocarcinoma cell lines. The ectopic expression of p33(ING1b) mediated by Ad-ING1b resulted in decreased growth, increased apoptosis, and cell cycle arrest at the G1 phase in both benign and malignant gastric epithelial cells regardless of their p53 status. Addition of a p53 inhibitor, pifithrin-α, did not abolish the pro-apoptotic and cell cycle-arresting effects of p33(ING1b) in p53 wild-type cells.

Conclusions: Down-regulation of p33(ING1b) might play an important role in the development of gastric adenocarcinoma. Targeted local expression of p33(ING1b) may offer a promising alternative therapeutic measure for gastric cancer.

Citing Articles

Oncolytic virus: A catalyst for the treatment of gastric cancer.

Wang J, Du L, Chen X Front Oncol. 2022; 12:1017692.

PMID: 36505792 PMC: 9731121. DOI: 10.3389/fonc.2022.1017692.

The effect of cullin 4A on lung cancer cell chemosensitivity to paclitaxel through p33ING1b regulation.

Lung J, Chen Y, Lin Y, Li Y, You L, Jablons D Am J Transl Res. 2021; 13(10):11194-11208.

PMID: 34786051 PMC: 8581858.

INGs are potential drug targets for cancer.

Zhang R, Jin J, Shi J, Hou Y J Cancer Res Clin Oncol. 2016; 143(2):189-197.

PMID: 27544390 DOI: 10.1007/s00432-016-2219-z.

Ectopic expression of p33 suppresses proliferation and induces apoptosis in colonic adenocarcinoma cells.

Jia A, Lv Y, Guo X, Ren L, Qin J Oncol Lett. 2015; 10(3):1517-1522.

PMID: 26622701 PMC: 4533300. DOI: 10.3892/ol.2015.3385.

References

Shinoura N, Muramatsu Y, Nishimura M, Yoshida Y, Saito A, Yokoyama T . Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res. 1999; 59(21):5521-8. View

Ythier D, Larrieu D, Brambilla C, Brambilla E, Pedeux R . The new tumor suppressor genes ING: genomic structure and status in cancer. Int J Cancer. 2008; 123(7):1483-90. DOI: 10.1002/ijc.23790. View

Tallen G, Riabowol K, Wolff J . Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells. Anticancer Res. 2003; 23(2B):1631-5. View

Ohgi T, Masaki T, Nakai S, Morishita A, Yukimasa S, Nagai M . Expression of p33(ING1) in hepatocellular carcinoma: relationships to tumour differentiation and cyclin E kinase activity. Scand J Gastroenterol. 2003; 37(12):1440-8. DOI: 10.1080/003655202762671332. View

Garkavtsev I, Kazarov A, Gudkov A, Riabowol K . Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet. 1996; 14(4):415-20. DOI: 10.1038/ng1296-415. View

Chen L, Matsubara N, Yoshino T, Nagasaka T, Hoshizima N, Shirakawa Y . Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. Cancer Res. 2001; 61(11):4345-9. View

Nouman G, Angus B, Lunec J, Crosier S, Lodge A, Anderson J . Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues. Hybrid Hybridomics. 2002; 21(1):1-10. DOI: 10.1089/15368590252917584. View

Ito K, Kinjo K, Nakazato T, Ikeda Y, Kizaki M . Expression and sequence analyses of p33(ING1) gene in myeloid leukemia. Am J Hematol. 2002; 69(2):141-3. DOI: 10.1002/ajh.10031. View

Tsang F, Po L, Leung K, Lau A, Siu W, Poon R . ING1b decreases cell proliferation through p53-dependent and -independent mechanisms. FEBS Lett. 2003; 553(3):277-85. DOI: 10.1016/s0014-5793(03)01024-x. View

10.

Gunduz M, Ouchida M, Fukushima K, Hanafusa H, Etani T, Nishioka S . Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res. 2000; 60(12):3143-6. View

11.

Goeman F, Thormeyer D, Abad M, Serrano M, Schmidt O, Palmero I . Growth inhibition by the tumor suppressor p33ING1 in immortalized and primary cells: involvement of two silencing domains and effect of Ras. Mol Cell Biol. 2004; 25(1):422-31. PMC: 538761. DOI: 10.1128/MCB.25.1.422-431.2005. View

12.

Nouman G, Anderson J, Mathers M, Leonard N, Crosier S, Lunec J . Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. Histopathology. 2002; 40(4):360-6. DOI: 10.1046/j.1365-2559.2002.01369.x. View

13.

Zhu Z, Lin J, Qu J, Feitelson M, Ni C, Li F . Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma. World J Gastroenterol. 2005; 11(13):1903-9. PMC: 4305709. DOI: 10.3748/wjg.v11.i13.1903. View

14.

Gong W, Suzuki K, Russell M, Riabowol K . Function of the ING family of PHD proteins in cancer. Int J Biochem Cell Biol. 2005; 37(5):1054-65. DOI: 10.1016/j.biocel.2004.09.008. View

15.

Shen D, Chan K, Khoo U, Ngan H, Xue W, Chiu P . Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis. 2005; 26(4):855-63. DOI: 10.1093/carcin/bgi011. View

16.

Coles A, Liang H, Zhu Z, Marfella C, Kang J, Imbalzano A . Deletion of p37Ing1 in mice reveals a p53-independent role for Ing1 in the suppression of cell proliferation, apoptosis, and tumorigenesis. Cancer Res. 2007; 67(5):2054-61. PMC: 2872148. DOI: 10.1158/0008-5472.CAN-06-3558. View

17.

Nouman G, Anderson J, Crosier S, Shrimankar J, Lunec J, Angus B . Downregulation of nuclear expression of the p33(ING1b) inhibitor of growth protein in invasive carcinoma of the breast. J Clin Pathol. 2003; 56(7):507-11. PMC: 1770004. DOI: 10.1136/jcp.56.7.507. View

18.

Zhu J, Li F, Zhu X, Liao W . The p33ING1b tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Life Sci. 2005; 78(13):1469-77. DOI: 10.1016/j.lfs.2005.07.044. View

19.

Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A . Suppression of ING1 expression in sporadic breast cancer. Oncogene. 1999; 18(37):5187-93. DOI: 10.1038/sj.onc.1202905. View

20.

Garkavtsev I, Demetrick D, Riabowol K . Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1). Cytogenet Cell Genet. 1997; 76(3-4):176-8. DOI: 10.1159/000134539. View